Literature DB >> 20878112

Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.

J D Schultz1, G Bran, C Anders, H Sadick, A Faber, K Hörmann, A Sauter.   

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) presents at a locally advanced (LA) stage in many patients. Chemotherapy, which is one fundamental therapy mode for local disease control of inoperable disease or if organ preservation is desired, has become an important factor of first line treatment regimens either during or prior to radiotherapy (RT). Patients with locoregionally advanced inoperable, recurrent or metastatic disease still have a poor prognosis, which enforces the need for new treatment approaches and new drug therapies, adjusted to the different settings of the disease. One innovative progress for this collective of patients with locally advanced tumor was the implementation of Docetaxel in chemotherapeutic regimes in optimal combination with concurrent chemoradiotherapy or in neoadjuvant setting of induction phase treatment. Docetaxel combined with the conventional chemotherapy regimen, containing Cisplatin and 5-Fluorouracil (TPF), is now acknowledged as being the gold standard of induction treatment. Various studies suggest survival advantage due to the induction chemotherapy (ICT) followed by chemoradiotherapy, which is known as sequential therapy, over chemoradiotherapy alone. In contrast to prevailing studies we administered Docetaxel, Carboplatin and 5-FU within the frame-work of induction chemotherapy instead of conventional use of Cisplatin for five patients with locoregionally advanced HNSCC. The clinical progress was evaluated through cross section imaging (computer tomography/MRI) prior and after ICT and classified following the RECIST criteria. Due to a very small collective of patient and the administration of Carboplatin instead of Cisplatin in this study, it was not possible to document the the efficacy of ICT (TPF) concerning survival advantage in patient with locoregionally advanced head and neck tumors. Further studies with an extended collective of patients are neccessary.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20878112     DOI: 10.3892/or_00000974

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  IL-6 stabilizes Twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2.

Authors:  Ying-Wen Su; Tong-Xin Xie; Daisuke Sano; Jeffrey N Myers
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

2.  p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells.

Authors:  Kanika Sharma; Thien-Trang Vu; Wade Cook; Mitra Naseri; Kevin Zhan; Wataru Nakajima; Hisashi Harada
Journal:  Mol Oncol       Date:  2018-04-17       Impact factor: 6.603

3.  Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment.

Authors:  Erin L Britt; Sarina Raman; Kendall Leek; Casey H Sheehy; Sung W Kim; Hisashi Harada
Journal:  PLoS One       Date:  2019-07-05       Impact factor: 3.240

4.  Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.

Authors:  Xin Tian; Ying Xuan; Rong Wu; Song Gao
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

Review 5.  Targeting Stress-Response Pathways and Therapeutic Resistance in Head and Neck Cancer.

Authors:  Tasia Bos; J Alex Ratti; Hisashi Harada
Journal:  Front Oral Health       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.